99.61BMarket Cap-15116P/E (TTM)
49.150High48.200Low9.41MVolume48.250Open48.240Pre Close460.40MTurnover0.47%Turnover Ratio12.73P/E (Static)2.03BShares56.65652wk High5.85P/B99.43BFloat Cap39.03652wk Low2.37Dividend TTM2.02BShs Float75.683Historical High4.82%Div YieldTTM1.97%Amplitude8.383Historical Low48.911Avg Price1Lot Size
Bristol-Myers Squibb Stock Forum
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
Gapping up
$Royal Philips (PHG.US)$ experienced a significant boost of 10.6% after the company reported robust second-quarter earnings, attributing much of their success to cost-saving measures, including workforce reductions, and a substantial insurance payout related to liability claims.
$Tesla (TSLA.US)$ 's shares advanced by 1.9% following an endorsement by Morgan Stanley analyst Adam Jonas, naming it the top ...
Do you think this is a right move?
Sell AON at 320.62, profit ratio +13.33%
Sell BLK at 843.83, profit ratio +9.88%
Gapping up
$Coinbase (COIN.US)$ 's stock saw a 5.2% increase as it followed the rise in bitcoin prices, with the leading cryptocurrency up approximately 4% after a downturn the previous day.
Semiconductor stocks experienced a rebound, with $NVIDIA (NVDA.US)$ , $Broadcom (AVGO.US)$ , $Qualcomm (QCOM.US)$ , and $Micron Technology (MU.US)$ all posting gains exceeding 2%. This movement came as the sector attempted to r...
📊⚡️📊
No comment yet